Evidence map›Paper›PMID 38709069›Full record

ArticleCancer research communications2024

Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence.

Frank A Sinicrope, Garth D Nelson, Bahar Saberzadeh-Ardestani, Diana I Segovia, Rondell P Graham, Christina Wu, Catherine E Hagen, Sameer Shivji, Paul Savage, Dan D Buchanan and 17 more

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Frank A SinicropeDepartments of Medicine and Oncology, Rochester, Minnesota.ORCID 0000-0002-2907-1000
Garth D NelsonDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0002-0709-1155
Bahar Saberzadeh-ArdestaniGastrointestinal Research Unit, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-7244-1839
Diana I SegoviaDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0002-5859-190X
Rondell P GrahamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8686-4867
Christina WuDivision of Medical Oncology, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0001-5922-5392
Catherine E HagenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1867-4957
Sameer ShivjiDepartment of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-6690-9239
Paul SavageMount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0003-2881-6717
Dan D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-2225-6675
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-8964-6160
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-1446-2201
Carol SwallowLunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.ORCID 0000-0001-9313-3133
Loic LeMarchandDepartment of Epidemiology, University of Hawaii, Honolulu, Hawaii.ORCID 0000-0001-5013-980X
Steven GallingerLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6998-9414
Robert C GrantDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0002-9821-0377
Reetesh K PaiDepartment of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-4770-2926
Stephen N SinicropeUniversity of Chicago Medical Center, Chicago, Illinois.ORCID 0000-0003-0986-1686
Dongyao YanRoche Tissue Diagnostics, Tucson, Arizona.ORCID 0009-0001-9482-3539
Kandavel ShanmugamRoche Tissue Diagnostics, Tucson, Arizona.ORCID 0000-0002-9076-3444
James ConnerDepartment of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0003-2227-6182
David P CyrLunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.ORCID 0000-0001-8463-3064
Richard KirschDepartment of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-2013-6541
Imon BanerjeeDepartment of Radiology and Machine Intelligence in Medicine and Imaging Center (MI-2), Mayo Clinic Arizona, Phoenix, Arizona.ORCID 0000-0002-3327-8004
Steve R AlbertsDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5835-4122
Qian ShiDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4640-8832
Rish K PaiDepartment of Pathology and Laboratory Medicine, Mayo Clinic, Arizona.ORCID 0000-0002-2692-221X

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon CancerR01CA210509 · NCI · MAYO CLINIC ROCHESTER · PI SINICROPE, FRANK A. · 2017 to 2021
$2.0M
HHS | NIH | NCI | Center for Cancer Research (CCR) U10CA180821, U10CA180882, U24CA196171Mayo Clinic (The Mayo Clinic) Departments Engaging Research for InnoVation (DERIVE) awardNCI NIH HHS R01 CA210509NCI NIH HHS U01 CA167551NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171Sanofi (Sanofi US)
6 · The paper itself

Abstract

Deep learning may detect biologically important signals embedded in tumor morphologic features that confer distinct prognoses. Tumor morphologic features were quantified to enhance patient risk stratification within DNA mismatch repair (MMR) groups using deep learning. Using a quantitative segmentation algorithm (QuantCRC) that identifies 15 distinct morphologic features, we analyzed 402 resected stage III colon carcinomas [191 deficient (d)-MMR; 189 proficient (p)-MMR] from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy. Results were validated in an independent cohort (176 d-MMR; 1,094 p-MMR). Association of morphologic features with clinicopathologic variables, MMR, KRAS, BRAFV600E, and time-to-recurrence (TTR) was determined. Multivariable Cox proportional hazards models were developed to predict TTR. Tumor morphologic features differed significantly by MMR status. Cancers with p-MMR had more immature desmoplastic stroma. Tumors with d-MMR had increased inflammatory stroma, epithelial tumor-infiltrating lymphocytes (TIL), high-grade histology, mucin, and signet ring cells. Stromal subtype did not differ by BRAFV600E or KRAS status. In p-MMR tumors, multivariable analysis identified tumor-stroma ratio (TSR) as the strongest feature associated with TTR [HRadj 2.02; 95% confidence interval (CI), 1.14-3.57; P = 0.018; 3-year recurrence: 40.2% vs. 20.4%; Q1 vs. Q2-4]. Among d-MMR tumors, extent of inflammatory stroma (continuous HRadj 0.98; 95% CI, 0.96-0.99; P = 0.028; 3-year recurrence: 13.3% vs. 33.4%, Q4 vs. Q1) and N stage were the most robust prognostically. Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphologic differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis. SIGNIFICANCE: A deep learning algorithm can quantify tumor morphologic features that may reflect underlying mechanisms driving prognosis within MMR groups. TSR was the most robust morphologic feature associated with TTR in p-MMR colon cancers. Extent of inflammatory stroma and N stage were the strongest prognostic features in d-MMR tumors. TIL density was not independently prognostic in either MMR group.

Indexed as

Colonic NeoplasmsDeep LearningDNA Mismatch RepairNeoplasm Recurrence, LocalTumor MicroenvironmentAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleFluorouracilHumansLeucovorinMaleMiddle AgedOrganoplatinum CompoundsPrognosisFluorouracilLeucovorinOrganoplatinum Compounds

Identifiers

PMID38709069
PMCPMC11114095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.